Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450866 · ClinicalTrials.gov registry record · Phase 2
Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
A Phase 2 study of Breast Cancer and Metastatic Cancer, sponsored by David Peereboom, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 5
- Study locations
NCT00450866: Completed Phase 2 study of Breast Cancer and Metastatic Cancer, sponsored by David Peereboom, MD.
NCT00450866 is a Phase 2 study of Breast Cancer and Metastatic Cancer that has completed, run by David Peereboom, MD. The registered enrollment target is 55 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00450866, a Phase 2 study of Breast Cancer and Metastatic Cancer, has completed, sponsored by David Peereboom, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from breast cancer.
Primary Outcome
The number of patients that are documented to have progression free survival at 3 months after treatment. Progression free is define as \<25% increase in tumor area. PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death.
Conditions Studied
Interventions
- BIOLOGICAL epothilone B
Study Locations (5)
Ohio
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center - Cleveland
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
What the finished NCT00450866 record still lists
NCT00450866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which epothilone B is the first listed.
NCT00450866 lists 5 locations in 4 states (Ohio, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT00450866 about?
NCT00450866 is a clinical study titled "Epothilone B in Treating Patients With CNS Metastases From Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as epothilone B, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well epothilone B works in treating patients with CNS metastases from br...
What is the current status of trial NCT00450866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2007-01. Estimated completion is 2012-05.
What conditions does trial NCT00450866 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT00450866?
The interventions under investigation include: epothilone B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00450866?
This trial is sponsored by David Peereboom, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00450866 being conducted?
This trial has 5 study locations across Massachusetts, Michigan, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00450866's enrollment target sits among peer trials
55 767th of 1224 higher than 452 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia